Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757353 | 1.00 | PTGER4 (0.43) | PTGER4PTGER3PTGER2SMN1; SMN2TSHR | |
| SCHEMBL5215820 | 0.94 | PTGER4 (0.42) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4381445 | 0.86 | PTGER4 (0.40) | PTGER4PTGER3PTGER2SMN1; SMN2EPHX2 | |
| SCHEMBL4381437 | 0.86 | PTGER4 (0.40) | PTGER4PTGER3PTGER2SMN1; SMN2EPHX2 | |
| SCHEMBL756673 | 0.83 | PTGER4 (0.51) | PTGER4PTGER3PTGER2 | |
| SCHEMBL756672 | 0.83 | PTGER4 (0.51) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14463696 | 0.81 | PTGER4 (0.39) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5502471 | 0.80 | PTGER4 (0.46) | PTGER4 | |
| SCHEMBL755589 | 0.80 | PTGER4 (0.41) | PTGER4PTGER3PTGER2 | |
| SCHEMBL755588 | 0.80 | PTGER4 (0.41) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761495-B1 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7435746-B2 | 5-thiopiperdinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435746-B2 | 5-thiopiperdinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1761495-A2 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | Allergan Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20060281713-A1 | 5-Thiopiperdinyl prostaglandin e analogs | OLD DAVID W | 2006-12-14 | — | — | US | disclosed |
| WO-2005121086-A2 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281713-A1 | 5-Thiopiperdinyl prostaglandin e analogs | PTGES, PTGES2, ALOX5 | PTGER4 11/4885PTGER3 16/4885PTGER2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.